Vir Biotechnology VIR 深 滬
等待開盤 09-20 09:30:00 美东时间
7.94
+0.140
+1.79%
華盛通- 最 高8.14
- 今 開8.02
- 成交量 59.31万股
- 最 低 7.83
- 昨 收 7.80
- 總市值 10.64亿
- 52周最高 13.09
- 市盈率 靜 --
- 換手率 0.44%
- 52周最低 7.41
- 委 比 -82.12%
- 總股本 1.34亿
- 歷史最高 141.01
- 量 比 0.72
- 振 幅 3.97%
- 歷史最低 7.41
- 每 手 1
- 風險率 0.96%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Executive reshuffles: LLY, S and RY Companies in focus
Market watchers, throughout the week, observed several Wall Street executives stepping up for new roles as part of leadership reshuffling. Meanwhile, some companies such as Eli Lilly, SentinelOne and ...
09-15 04:21
Vir Biotechnology names Jason O’Byrne as CFO
Vir Biotechnology (NASDAQ:VIR) said it has appointed Jason O’Byrne as its CFO and executive vice president. The appointment is effective from October 2. Mr. O’Byrne is an industry veteran with over tw...
09-10 20:32
快讯 | vir biotechnology宣布与赛诺菲安万特达成独家全球许可协议，涉及多个潜在的一流临床阶段t-电芯抗体
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement Wi...
09-10 04:05
Breaking Down Vir Biotechnology: 6 Analysts Share Their Views
In the latest quarter, 6 analysts provided ratings for Vir Biotechnology (NASDA...
08-02 23:01
Vir Biotechnology Analyst Ratings
Unity Software(U.US) reported fourth-quarter financial results after the market...
08-02 22:10
快讯 | 瑞博生物技术公司：美银全球研究将目标股价从14美元上调至16美元
Vir Biotechnology Inc : BofA Global Research Raises Price Objective to $16 From...
08-02 20:33
快讯 | 巴克莱银行将目标价从27美元上调至28美元，针对Vir Biotechnology。
Vir Biotechnology : Barclays Raises Target Price to $28 From $27
08-02 18:57
Vir announces major restructuring, licensing deal with Sanofi
Vir Biotechnology (NASDAQ:VIR) said it is winding down several programs and licensing three new clinical assets from Sanofi (SNY) as part of a major restructuring. As part of its Q2 earnings report on...
08-02 05:27
快讯 | Vir Biotechnology: 与员工遣散现金支付有关的重组费用估计为1100万美元-1300万美元，预计在2024年下半年确认。
Vir Biotechnology: Restructuring Expenses Estimated at $11 Mln-$13 Mln, Related...
08-02 04:40
Vir Biotechnology Q2 2024 Adj EPS $(1.02) Misses $(0.90) Estimate, Sales $3.10M Miss $7.50M Estimate
Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(1.02) per share which missed the analyst consensus estimate of $(0.90) by 13.33 percent. The company reported quarterly sales of $3.10 million which missed
08-02 04:21
